Interferon alfa-2b for decompensated liver disease caused by either chronic hepatitis B or C: preliminary results of a pilot study.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 8314470.
- Also identified by PMC identifier 1374026.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This pilot study was designed to assess the tolerance and effectiveness of interferon alfa-2b in patients with decompensated liver disease caused by chronic hepatitis B (n = 7) or C (n = 5). Preliminary results suggest that patients may benefit from small doses of interferon (improvement in liver function tests and reduction in alanine aminotransferase), although the decreased tolerance and dose dependent increase in side effects in these patients with liver disease underlines the need for close follow up and the dose adjustment of interferon treatment.
Medical subject headings
- Hepatitis B
- Hepatitis C
- Interferon-alpha
- Liver Cirrhosis